Your browser doesn't support javascript.
loading
NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression.
Latif, Muhammad Umair; Schmidt, Geske Elisabeth; Mercan, Sercan; Rahman, Raza; Gibhardt, Christine Silvia; Stejerean-Todoran, Ioana; Reutlinger, Kristina; Hessmann, Elisabeth; Singh, Shiv K; Moeed, Abdul; Rehman, Abdul; Butt, Umer Javed; Bohnenberger, Hanibal; Stroebel, Philipp; Bremer, Sebastian Christopher; Neesse, Albrecht; Bogeski, Ivan; Ellenrieder, Volker.
Afiliação
  • Latif MU; Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Gottingen, Niedersachsen, Germany.
  • Schmidt GE; Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Gottingen, Niedersachsen, Germany.
  • Mercan S; Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Gottingen, Niedersachsen, Germany.
  • Rahman R; Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Gibhardt CS; Molecular Physiology, Institute of Cardiovascular Physiology, University Medical Center Göttingen, Gottingen, Niedersachsen, Germany.
  • Stejerean-Todoran I; Molecular Physiology, Institute of Cardiovascular Physiology, University Medical Center Göttingen, Gottingen, Niedersachsen, Germany.
  • Reutlinger K; Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Gottingen, Niedersachsen, Germany.
  • Hessmann E; Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Gottingen, Niedersachsen, Germany.
  • Singh SK; Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Gottingen, Niedersachsen, Germany.
  • Moeed A; Institute for Microbiology and Hygiene, Medical Center-University of Freiburg, Freiburg, Baden-Württemberg, Germany.
  • Rehman A; Institute of Pharmacology and Toxicology, University Medical Center Göttingen, Gottingen, Niedersachsen, Germany.
  • Butt UJ; Clinical Neuroscience, Max-Planck-Institute for Experimental Medicine, Goettingen, Niedersachsen, Germany.
  • Bohnenberger H; Institute of Pathology, University Medical Center Göttingen, Gottingen, Germany.
  • Stroebel P; Institute of Pathology, University Medical Center Göttingen, Gottingen, Germany.
  • Bremer SC; Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Gottingen, Niedersachsen, Germany.
  • Neesse A; Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Gottingen, Niedersachsen, Germany.
  • Bogeski I; Molecular Physiology, Institute of Cardiovascular Physiology, University Medical Center Göttingen, Gottingen, Niedersachsen, Germany.
  • Ellenrieder V; Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Gottingen, Niedersachsen, Germany volker.ellenrieder@med.uni-goettingen.de.
Gut ; 71(12): 2561-2573, 2022 12.
Article em En | MEDLINE | ID: mdl-35365570
ABSTRACT

OBJECTIVES:

Non-alcoholic fatty liver disease (NAFLD) can persist in the stage of simple hepatic steatosis or progress to steatohepatitis (NASH) with an increased risk for cirrhosis and cancer. We examined the mechanisms controlling the progression to severe NASH in order to develop future treatment strategies for this disease.

DESIGN:

NFATc1 activation and regulation was examined in livers from patients with NAFLD, cultured and primary hepatocytes and in transgenic mice with differential hepatocyte-specific expression of the transcription factor (Alb-cre, NFATc1c.a . and NFATc1Δ/Δ ). Animals were fed with high-fat western diet (WD) alone or in combination with tauroursodeoxycholic acid (TUDCA), a candidate drug for NAFLD treatment. NFATc1-dependent ER stress-responses, NLRP3 inflammasome activation and disease progression were assessed both in vitro and in vivo.

RESULTS:

NFATc1 expression was weak in healthy livers but strongly induced in advanced NAFLD stages, where it correlates with liver enzyme values as well as hepatic inflammation and fibrosis. Moreover, high-fat WD increased NFATc1 expression, nuclear localisation and activation to promote NAFLD progression, whereas hepatocyte-specific depletion of the transcription factor can prevent mice from disease acceleration. Mechanistically, NFATc1 drives liver cell damage and inflammation through ER stress sensing and activation of the PERK-CHOP unfolded protein response (UPR). Finally, NFATc1-induced disease progression towards NASH can be blocked by TUDCA administration.

CONCLUSION:

NFATc1 stimulates NAFLD progression through chronic ER stress sensing and subsequent activation of terminal UPR signalling in hepatocytes. Interfering with ER stress-responses, for example, by TUDCA, protects fatty livers from progression towards manifest NASH.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hepatopatia Gordurosa não Alcoólica Limite: Animals Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hepatopatia Gordurosa não Alcoólica Limite: Animals Idioma: En Ano de publicação: 2022 Tipo de documento: Article